title: Neurocognitive impairment in HIV-infected naïve patients with advanced disease: the role of virus and intrathecal immune activation.
abstract: OBJECTIVE
  To investigate intrathecal immune activation parameters and HIV-RNA in HIV-associated neurocognitive disorders (HAND) of advanced naïve HIV-infected patients and to evaluate their dynamics before and after initiation of antiretroviral therapy (ART).
  
  
  METHODS
  Cross-sectional and longitudinal analysis of HIV RNA, proinflammatory cytokines (IL-6, IL-10, INF-γ, TNF-α, TGF-β1, and TGF-β2) and chemokines (MIP-1α, MIP-1β, and MCP-1) in plasma and cerebrospinal fluid (CSF) of HIV-infected patients with CD4 <200/μL.
  
  
  RESULTS
  HAND was diagnosed at baseline in 6/12 patients. Baseline CSF HIV-RNA was comparable in patients with or without HAND, whereas CSF concentration of IL-6 and MIP-1β, proinflammatory cytokines, was increased in HAND patients. CSF evaluation at 12 weeks was available in 10/12 cases. ART greatly reduced HIV-RNA in all patients. Nevertheless, IL-6 and MIP-1β remained elevated after 12 weeks of therapy in HAND patients, in whom CSF HIV RNA decay was slower than the plasmatic one as well.
  
  
  CONCLUSIONS
  Immune activation, as indicated by inflammatory cytokines, but not higher levels of HIV-RNA is observed in advanced naïve HIV-infected patients with HAND. In HAND patients, ART introduction resulted in a less rapid clearance of CSF viremia compared to plasma and no modifications of intratechal immune activation.
authors.affiliation: Division of Infectious Diseases, Department of Internal Medicine, San Gerardo Hospital, University of Milan-Bicocca, 20900 Monza, Italy.
authors.forename: Monica
authors.initials: M
authors.lastname: Airoldi
authors.forename: Alessandra
authors.initials: A
authors.lastname: Bandera
authors.forename: Daria
authors.initials: D
authors.lastname: Trabattoni
authors.forename: Benedetta
authors.initials: B
authors.lastname: Tagliabue
authors.forename: Beatrice
authors.initials: B
authors.lastname: Arosio
authors.forename: Alessandro
authors.initials: A
authors.lastname: Soria
authors.forename: Veronica
authors.initials: V
authors.lastname: Rainone
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Lapadula
authors.forename: Giorgio
authors.initials: G
authors.lastname: Annoni
authors.forename: Mario
authors.initials: M
authors.lastname: Clerici
authors.forename: Andrea
authors.initials: A
authors.lastname: Gori
mesh_terms: D015526:AIDS Dementia Complex / Q000209:etiology / Q000276:immunology / Q000821:virology; D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D003072:Cognition Disorders / Q000209:etiology / Q000276:immunology* / Q000821:virology; D003430:Cross-Sectional Studies; D016207:Cytokines / Q000096:biosynthesis / Q000134:cerebrospinal fluid* / Q000276:immunology; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000097:blood / Q000134:cerebrospinal fluid* / Q000276:immunology; D019562:Viral Load; D014779:Virus Replication
chemical_list: D019380:Anti-HIV Agents; D016207:Cytokines; D012367:RNA, Viral